Reset gene networks to reverse disease, starting wtih siRNA for obesity
TRANSCRIPTIONAL DAMAGE
Many complex and age-related diseases exhibit widespread gene dysregulation.
However, most drug discovery only targets a single dysregulated gene.
BREAKTHROUGH SCIENCE
Junevity founders were the first to show that repression of a single transcription factor can restore gene networks to a healthy state in a human cell model of aging (PNAS, 2026).
This discovery unlocks novel siRNA therapeutics to reverse disease with a safe, proven modality.
JUNEVITY RESET PLATFORM
RESET discovers novel therapeutic candidates with human disease data, genetics, machine learning and siRNA.
This approach offers a path to safe therapeutics with genetic evidence to reset the health of our tissues, one disease at a time.
Learn more here.
THERAPEUTICS DEVELOPMENT
Junevity’s initial programs are in siRNA for obesity, where unmet need remains in tolerability and dosing frequency. JUN_02 is a novel dual-targeted siRNA with the potential for GLP-1-like weight loss, reduced GI side effects and infrequent 2x per year dosing. See our pipeline here.
We imagine a world with longer, healthier lives for all, powered by restoration of gene networks with siRNA.